Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,409 total articles

Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)

Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)

Mineralys Therapeutics announced new late-breaking data from its Phase 2 and Phase 3 trials showing that lorundrostat, a selective aldosterone synthase inhibitor, modulates heart failure risk biomarkers in patients with uncontrolled hypertension. The data will be presented at the Endocrine Society's annual meeting, highlighting lorundrostat's effic…

Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives

Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives

Tonix Pharmaceuticals announced it has secured a second commercial payer agreement effective June 1, 2026, with a leading group purchasing organization (GPO), increasing commercial insurance coverage of its fibromyalgia drug TONMYA® to approximately 52 million U.S. lives. This milestone follows an earlier agreement and enhances patient access to th…

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

Kymera Therapeutics announced new preclinical data for KT-579, an oral IRF5 degrader showing disease-modifying effects in lupus models by targeting multiple inflammatory pathways. The ongoing Phase 1 trial in healthy volunteers aims to assess safety and biological activity, with results anticipated in the second half of 2026. Success could pave the…

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

Tango Therapeutics reported highly positive initial data from an ongoing Phase 1/2 clinical trial testing the combination of vopimetostat, a PRMT5 inhibitor, with daraxonrasib, a RAS(ON) inhibitor, in patients with second and third line MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC). The combination showed a 92% obje…

Devon Announces Results of Early Participation in Private Exchange Offers and Consent Solicitations and Extension of Deadline to Receive Total Exchange Consideration

Devon Announces Results of Early Participation in Private Exchange Offers and Consent Solicitations and Extension of Deadline to Receive Total Exchange Consideration

Devon Energy Corporation announced significant early participation in its exchange offers and consent solicitations related to outstanding notes issued by its subsidiary, Coterra Energy Inc. Eligible holders have tendered a high percentage of notes, and Coterra has received the necessary consents to adopt proposed amendments. The deadline to receiv…

SUNation Energy and Suniva Enter Definitive Merger Agreement, Creating a Platform for American Solar Manufacturing and Services Leadership

SUNation Energy and Suniva Enter Definitive Merger Agreement, Creating a Platform for American Solar Manufacturing and Services Leadership

SUNation Energy, Inc., a Nasdaq-listed solar energy provider, and Suniva, the largest U.S.-owned solar cell manufacturer, have entered into a definitive merger agreement to combine their operations under the Suniva name. The merger aims to accelerate U.S. solar cell manufacturing capacity expansion, enhance domestic supply chain resilience, and bro…

Genco Shipping & Trading Limited Announces Leading Proxy Advisor ISS Joins Glass Lewis and Egan-Jones in Recommending Shareholders Vote “FOR” ALL of Genco’s Director Nominees

Genco Shipping & Trading Limited Announces Leading Proxy Advisor ISS Joins Glass Lewis and Egan-Jones in Recommending Shareholders Vote “FOR” ALL of Genco’s Director Nominees

Genco Shipping & Trading Limited announced that top proxy advisory firms ISS, Glass Lewis, and Egan-Jones recommend shareholders vote for all of Genco's director nominees and against proposals from rival Diana Shipping Inc., amid an unsolicited tender offer dispute. The endorsements bolster Genco's board strategy and encourage shareholders to rejec…

Aeries Technology Reports Fiscal Year 2026 Results

Aeries Technology Reports Fiscal Year 2026 Results

Aeries Technology, Inc. announced fiscal year 2026 results with revenues of $70 million and net income of $3.5 million, a significant improvement from the previous year's losses. The company exceeded its adjusted EBITDA guidance and generated positive operating cash flow for the fourth consecutive quarter. It launched the AeriesOne A1 GCC Platform …

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Artiva Biotherapeutics presented encouraging clinical data on AlloNK, their off-the-shelf NK cell therapy combined with rituximab, showing deep B-cell depletion and meaningful clinical responses in refractory rheumatoid arthritis (RA) and other autoimmune diseases at EULAR 2026. The FDA granted RMAT designation to AlloNK for refractory RA, supporti…

HP Recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for Digital Employee Experience (DEX) Management Tools

HP Recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for Digital Employee Experience (DEX) Management Tools

HP Inc. has been named a Leader in Gartner's 2026 Magic Quadrant for Digital Employee Experience (DEX) Management Tools. This recognition highlights HP's Workforce Experience Platform (WXP) for its comprehensive visibility, multi-vendor support, and AI-driven proactive management across devices and applications. HP emphasizes its strategic shift to…

Shattuck Labs Announces Phase 1 Results for SL-325

Shattuck Labs Announces Phase 1 Results for SL-325

Shattuck Labs announced positive Phase 1 trial results for SL-325, its lead monoclonal antibody targeting the DR3 receptor involved in inflammatory and immune-mediated diseases. The trial demonstrated favorable safety, durable receptor occupancy with complete TL1A blockade lasting over three months, and a low immunogenicity rate of 3.7%. The compan…

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

Lyell Immunopharma announced favorable safety data from its Phase 1 clinical trial of LYL273 in relapsed or refractory metastatic colorectal cancer, noting a significant reduction in severe gastrointestinal side effects through prophylaxis. The trial has been amended to a seamless Phase 1/2 design with expanded patient cohorts, including second-lin…

Lixiang Education Regains Compliance with Nasdaq Minimum Market Value of Publicly Held Shares Requirement

Lixiang Education Regains Compliance with Nasdaq Minimum Market Value of Publicly Held Shares Requirement

Lixiang Education Holding Co., Ltd., a private education services provider based in China, announced it has regained compliance with Nasdaq's minimum market value of publicly held shares requirement after its market value exceeded $5 million for ten consecutive business days ending June 4, 2026. This resolves a previous non-compliance issue noted i…

Pre-Feasibility Study for Grey Fox at Fox Complex — High Returns, Manageable Capital, Mine Life Extended to 2041

Pre-Feasibility Study for Grey Fox at Fox Complex — High Returns, Manageable Capital, Mine Life Extended to 2041

McEwen Inc. announced the results of the Pre-Feasibility Study (PFS) for its Grey Fox Project near Timmins, Ontario, extending the Fox Complex mine life to 2041 and projecting increased gold production. With an estimated initial capital expenditure of $181 million and robust economics assuming gold prices over $4,000/oz, the project is expected to …

Enigmatig Limited Issues Statement on Recent Share Trading Activity

Enigmatig Limited Issues Statement on Recent Share Trading Activity

Enigmatig Limited issued a statement responding to recent unusual trading activity in its shares on June 4 and 5, 2026. The company confirmed it is unaware of any new material information or developments that have not been previously disclosed. It reiterated its commitment to compliance with disclosure obligations under federal securities laws and …

American Battery Technology Company Wins Appeal and Has US Department of Energy Grant Reinstated for $115 million Project for Commercial Scale Critical Mineral Lithium Refinery

American Battery Technology Company Wins Appeal and Has US Department of Energy Grant Reinstated for $115 million Project for Commercial Scale Critical Mineral Lithium Refinery

American Battery Technology Company (NASDAQ: ABAT) successfully won an appeal to reinstate a $115 million U.S. Department of Energy grant supporting its Tonopah Flats Lithium Project, a major commercial-scale critical mineral lithium refinery in Nevada. The reinstatement follows a rigorous review confirming the project’s achievement of all technica…

Duluth Holdings Inc. Announces First Quarter 2026 Financial Results

Duluth Holdings Inc. Announces First Quarter 2026 Financial Results

Duluth Holdings Inc. announced its first quarter fiscal 2026 financial results, showing a net loss improvement to $10 million from $15.3 million in the prior year, and an increase in adjusted EBITDA by $6.4 million to $2.6 million. The company achieved a gross margin expansion of 540 basis points to 57.4%, reduced inventory significantly by 24.8%, …

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

Alvotech announced that the U.S. FDA has accepted its Biologics License Application for AVT16, an interchangeable biosimilar candidate to Entyvio® (vedolizumab). Developed in partnership with Teva Pharmaceutical, AVT16 targets treatment of ulcerative colitis and Crohn’s disease. The acceptance signifies progress toward potentially expanding patient…

Willis expands its international property facility with up to USD 60 million ‘Follow’ capacity per placement

Willis expands its international property facility with up to USD 60 million ‘Follow’ capacity per placement

Willis Towers Watson (WTW) announces the expansion of its international property facility, now providing up to $60 million follow capacity per placement supported by the Neuron algorithmic digital platform. The facility covers diverse regions including Europe, Asia, and Canada, and targets multiple sectors such as airports, leisure, industrial, inf…

Ingredion Announces Recommended All-Cash Acquisition of Tate & Lyle

Ingredion Announces Recommended All-Cash Acquisition of Tate & Lyle

Ingredion Incorporated (NYSE: INGR) has announced a recommended all-cash acquisition of Tate & Lyle PLC, a global leader in specialty ingredients, in a transaction valued at approximately $5.0 billion. The acquisition will combine complementary ingredient portfolios and geographic supply networks, enhancing Ingredion’s specialty ingredients platfor…